Clinical Trial Update: Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

View source ↗

Summary

Expanded access treatment with Lu-177-PNT2002 for adults with PSMA-positive metastatic castration-resistant prostate cancer, currently temporarily not available…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lu-177-PNT2002 (Lutetium-177 PNT2002)

Snippet

Sponsor: Lantheus Medical Imaging | Conditions: Castration-Resistant Prostatic Cancer | Status: TEMPORARILY_NOT_AVAILABLE